Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined drug for treating pancreatic cancer

A technology for pancreatic cancer and pharmaceutical preparations, applied in the field of combination drugs for the treatment of pancreatic cancer, can solve the problems of less than 30% treatment response rate, prolongation of median survival period, unsatisfactory treatment effect of pancreatic cancer, etc. Significant effect of growth inhibition

Active Publication Date: 2014-02-26
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current clinical chemotherapy regimens have not achieved a satisfactory therapeutic effect on pancreatic cancer. The response rate of the first-line chemotherapy drugs represented by gemcitabine is less than 30%, which can only prolong the treatment by 4-6 months. The median survival time of
However, there is no report on whether the combination of withaferin A (Withaferin A) and oxaliplatin shows anti-tumor effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined drug for treating pancreatic cancer
  • Combined drug for treating pancreatic cancer
  • Combined drug for treating pancreatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 In vitro cytotoxicity detection experiment of withaferin A combined with oxaliplatin

[0035] 1. Materials

[0036] Experimental drug configuration:

[0037] In this example, withaferin A was purchased from Santa Cruz Company in the United States, prepared into a concentrated solution with a concentration of 2 mg / mL with DMSO, and stored in a refrigerator at -20 ° C. During the experiment, it was diluted to different concentrations with culture medium as needed working fluid;

[0038] Oxaliplatin can be produced by known methods, for example, according to the methods described in US Pat. No. 5,338,874 (US5,338,874) and US Pat. No. 5,420,319 (US5,420,319). In addition, oxaliplatin can also be obtained by purchasing Eloxatin (registered trademark) from Sanofi Aventis.

[0039] In this example, oxaliplatin was purchased from Sanofi Aventis.

[0040] Other reagents: high-glucose DMEM, RPMI-1640, and fetal bovine serum (FBS) were purchased from Gibco, USA; cell...

Embodiment 2

[0050] The in vitro cytotoxicity detection experiment of embodiment 2 gemcitabine

[0051] 1. Materials

[0052] Experimental drug: Gemcitabine was purchased from Sigma Company in the United States, prepared into a concentrated solution with a concentration of 50mg / mL with DMSO, and stored in a -20°C refrigerator. During the experiment, it was diluted with culture medium to form working solutions of different concentrations;

[0053] Other reagents: high-glucose DMEM, RPMI-1640, and fetal bovine serum (FBS) were purchased from Gibco, USA; cell culture flasks and culture plates were purchased from Corning, USA; CCK-8 (cell counting kit- 8) The detection kit was purchased from Dojindo, Japan;

[0054] 2. Cells and cell culture

[0055] Human pancreatic cancer cell lines Panc-1, MiaPaCa-2 and Capan-2 were purchased from the American Type Culture Collection (ATCC); normal human liver cells L02 and normal human lung fibroblasts HLF1 were purchased from the Shanghai Cell Bank of t...

Embodiment 3

[0060] Example 3 Colony formation assay detects the inhibitory rate of drugs on cell growth

[0061] 1. Materials

[0062] Experimental drugs: withaferin A was purchased from Santa Cruz Company in the United States, prepared into a concentrated solution with a concentration of 2 mg / mL with DMSO, and stored in a -20°C refrigerator; oxaliplatin was purchased from Sanofi Aventis Company.

[0063] Other reagents: high-glucose DMEM and fetal bovine serum (Fatal Bovine Serum, FBS) were purchased from Gibco, USA; cell culture flasks and dishes were purchased from Corning, USA; 4% paraformaldehyde and crystal violet were purchased from Beijing Dingguo Changsheng Biotechnology Company.

[0064] 2. Cells and cell culture

[0065] Human pancreatic cancer cell lines Panc-1, MiaPaCa-2 and Capan-2 were purchased from the American Type Culture Collection (ATCC). Cell culture conditions: high glucose DMEM, 10% fetal bovine serum, 37°C, 5.0% CO 2 .

[0066] 3. Experimental steps

[0067]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a combined drug preparation for treating pancreatic cancer. Withaferin A and oxaliplatin are used by the combined drug preparation for treating the pancreatic cancer. The Withaferin A and oxaliplatin can be used for killing cancer cells through oxidative stress injury mediated by the ROS (reactive oxygen species), two ROS in different sources can be united to develop the synergistic effect after combined medication, and the effect of killing pancreatic cancer cells is obvious stronger than that of single medication. Under the concentration in which the combined drug does not generate obvious toxic effect on the normal cells, the growth inhibiting effect of the combined drug on the pancreatic cancer cells is more obvious than that of clinical first drugs gemcitabine for the pancreatic cancer, the result shows that the combined drug can be well applied to treatment of the pancreatic cancer and preparation of the drugs for treating the pancreatic cancer.

Description

technical field [0001] The invention relates to the field of treating pancreatic cancer, in particular to a combination medicine for treating pancreatic cancer. Background technique [0002] Pancreatic cancer is a digestive tract tumor with a high degree of malignancy and a very poor prognosis. In recent years, its incidence rate has been increasing year by year around the world. In the United States, the incidence rate of pancreatic cancer ranks tenth among malignant tumors, and its mortality rate ranks fourth; in China, with the continuous improvement of the national economy and people's living standards , the incidence of pancreatic cancer in malignant tumors has risen from 20th to 8th, and its mortality rate ranks 6th among malignant tumors. Therefore, pancreatic cancer has become one of the diseases that seriously threaten human health. [0003] Due to the special anatomical part of the pancreas, the early symptoms of pancreatic cancer are hidden. Most patients only s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/585A61P35/00A61K31/282
Inventor 秦仁义李旭王敏朱峰田锐石程剑贾伟梁盟彭丰郭兴军徐盟谢昱张航
Owner TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com